Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
5.24
-0.07 (-1.32%)
At close: Dec 5, 2025, 4:00 PM EST
5.28
+0.04 (0.76%)
After-hours: Dec 5, 2025, 7:59 PM EST
Altimmune Revenue
Altimmune had revenue of $5.00K in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $20.00K, down -61.54% year-over-year. In the year 2024, Altimmune had annual revenue of $20.00K, down -95.31%.
Revenue (ttm)
$20.00K
Revenue Growth
-61.54%
P/S Ratio
27,337.70
Revenue / Employee
$339
Employees
59
Market Cap
546.75M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20.00K | -406.00K | -95.31% |
| Dec 31, 2023 | 426.00K | 494.00K | -726.47% |
| Dec 31, 2022 | -68.00K | -4.48M | -101.54% |
| Dec 31, 2021 | 4.41M | -3.78M | -46.12% |
| Dec 31, 2020 | 8.19M | 2.38M | 41.09% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ALT News
- 4 days ago - Altimmune Announces CEO Transition and Succession Plan - GlobeNewsWire
- 9 days ago - Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 15 days ago - Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 21 days ago - Altimmune: Probing Pemvi's MASH Data - Seeking Alpha
- 24 days ago - Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025 - GlobeNewsWire
- 4 weeks ago - Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025 - GlobeNewsWire
- 4 weeks ago - Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Altimmune Announces Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire